U-50,488, saline and naltrexone discrimination in U-50,488-treated pigeons

Charles P France, J. H. Woods

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pigeons treated with 10.0 mg/kg/day of U-50,488 discriminated among intramuscular (i.m.) injections of U-50,488 (10 mg/kg), saline, and naltrexone (0.178 mg/kg), while responding under a fixed-ratio 20 schedule of food presentation. Training compounds occasioned responding on the appropriate keys with pigeons responding ≥ 90% on the naltrexone key at doses larger than 0.032 mg/kg of naltrexone, ≥ 90% on the U-50,488 key at doses larger than 3.2 mg/kg of U-50,488, and ≥ 90% on the saline key after saline. Several opioid agonists and antagonists were studied for their discriminative stimulus effects. None of the compounds substituted completely (≥ 90%) for either training compound in all pigeons (n = 5); however, bremazocine substituted completely for U-50,488 in three out of five pigeons. Compounds with opioid antagonist actions under other conditions substituted for naltrexone in some subjects: levallorphan, two out of five; nalbuphine, one out of five; nalorphine, two out of five; and quadazocine, three out of four. Morphine did not substitute for naltrexone or U-50,488 in any of the subjects. When U-50,488 treatment was terminated and subjects were studied daily after injections of saline, responding occurred predominantly on the saline key; the absence of naltrexone key responding after termination of U-50,488 treatment suggests that this dosing regimen was not adequate for the development of dependence, or that the discriminative stimulus effects of abstinence-induced withdrawal were qualitatively different from the discriminative stimulus effects of naltrexone under these conditions.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalBehavioural Pharmacology
Volume4
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Naltrexone
Columbidae
Narcotic Antagonists
Levallorphan
Nalorphine
Nalbuphine
Intramuscular Injections
Morphine
Appointments and Schedules
Food
Injections
Therapeutics

Keywords

  • dependence
  • drug discrimination
  • Kappa opioid
  • naltrexone
  • pigeon
  • U-50,488
  • withdrawal

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

U-50,488, saline and naltrexone discrimination in U-50,488-treated pigeons. / France, Charles P; Woods, J. H.

In: Behavioural Pharmacology, Vol. 4, No. 5, 1993, p. 509-516.

Research output: Contribution to journalArticle

@article{6c5e08946f4746c6976710471be21a4b,
title = "U-50,488, saline and naltrexone discrimination in U-50,488-treated pigeons",
abstract = "Pigeons treated with 10.0 mg/kg/day of U-50,488 discriminated among intramuscular (i.m.) injections of U-50,488 (10 mg/kg), saline, and naltrexone (0.178 mg/kg), while responding under a fixed-ratio 20 schedule of food presentation. Training compounds occasioned responding on the appropriate keys with pigeons responding ≥ 90{\%} on the naltrexone key at doses larger than 0.032 mg/kg of naltrexone, ≥ 90{\%} on the U-50,488 key at doses larger than 3.2 mg/kg of U-50,488, and ≥ 90{\%} on the saline key after saline. Several opioid agonists and antagonists were studied for their discriminative stimulus effects. None of the compounds substituted completely (≥ 90{\%}) for either training compound in all pigeons (n = 5); however, bremazocine substituted completely for U-50,488 in three out of five pigeons. Compounds with opioid antagonist actions under other conditions substituted for naltrexone in some subjects: levallorphan, two out of five; nalbuphine, one out of five; nalorphine, two out of five; and quadazocine, three out of four. Morphine did not substitute for naltrexone or U-50,488 in any of the subjects. When U-50,488 treatment was terminated and subjects were studied daily after injections of saline, responding occurred predominantly on the saline key; the absence of naltrexone key responding after termination of U-50,488 treatment suggests that this dosing regimen was not adequate for the development of dependence, or that the discriminative stimulus effects of abstinence-induced withdrawal were qualitatively different from the discriminative stimulus effects of naltrexone under these conditions.",
keywords = "dependence, drug discrimination, Kappa opioid, naltrexone, pigeon, U-50,488, withdrawal",
author = "France, {Charles P} and Woods, {J. H.}",
year = "1993",
language = "English (US)",
volume = "4",
pages = "509--516",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - U-50,488, saline and naltrexone discrimination in U-50,488-treated pigeons

AU - France, Charles P

AU - Woods, J. H.

PY - 1993

Y1 - 1993

N2 - Pigeons treated with 10.0 mg/kg/day of U-50,488 discriminated among intramuscular (i.m.) injections of U-50,488 (10 mg/kg), saline, and naltrexone (0.178 mg/kg), while responding under a fixed-ratio 20 schedule of food presentation. Training compounds occasioned responding on the appropriate keys with pigeons responding ≥ 90% on the naltrexone key at doses larger than 0.032 mg/kg of naltrexone, ≥ 90% on the U-50,488 key at doses larger than 3.2 mg/kg of U-50,488, and ≥ 90% on the saline key after saline. Several opioid agonists and antagonists were studied for their discriminative stimulus effects. None of the compounds substituted completely (≥ 90%) for either training compound in all pigeons (n = 5); however, bremazocine substituted completely for U-50,488 in three out of five pigeons. Compounds with opioid antagonist actions under other conditions substituted for naltrexone in some subjects: levallorphan, two out of five; nalbuphine, one out of five; nalorphine, two out of five; and quadazocine, three out of four. Morphine did not substitute for naltrexone or U-50,488 in any of the subjects. When U-50,488 treatment was terminated and subjects were studied daily after injections of saline, responding occurred predominantly on the saline key; the absence of naltrexone key responding after termination of U-50,488 treatment suggests that this dosing regimen was not adequate for the development of dependence, or that the discriminative stimulus effects of abstinence-induced withdrawal were qualitatively different from the discriminative stimulus effects of naltrexone under these conditions.

AB - Pigeons treated with 10.0 mg/kg/day of U-50,488 discriminated among intramuscular (i.m.) injections of U-50,488 (10 mg/kg), saline, and naltrexone (0.178 mg/kg), while responding under a fixed-ratio 20 schedule of food presentation. Training compounds occasioned responding on the appropriate keys with pigeons responding ≥ 90% on the naltrexone key at doses larger than 0.032 mg/kg of naltrexone, ≥ 90% on the U-50,488 key at doses larger than 3.2 mg/kg of U-50,488, and ≥ 90% on the saline key after saline. Several opioid agonists and antagonists were studied for their discriminative stimulus effects. None of the compounds substituted completely (≥ 90%) for either training compound in all pigeons (n = 5); however, bremazocine substituted completely for U-50,488 in three out of five pigeons. Compounds with opioid antagonist actions under other conditions substituted for naltrexone in some subjects: levallorphan, two out of five; nalbuphine, one out of five; nalorphine, two out of five; and quadazocine, three out of four. Morphine did not substitute for naltrexone or U-50,488 in any of the subjects. When U-50,488 treatment was terminated and subjects were studied daily after injections of saline, responding occurred predominantly on the saline key; the absence of naltrexone key responding after termination of U-50,488 treatment suggests that this dosing regimen was not adequate for the development of dependence, or that the discriminative stimulus effects of abstinence-induced withdrawal were qualitatively different from the discriminative stimulus effects of naltrexone under these conditions.

KW - dependence

KW - drug discrimination

KW - Kappa opioid

KW - naltrexone

KW - pigeon

KW - U-50,488

KW - withdrawal

UR - http://www.scopus.com/inward/record.url?scp=0027424534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027424534&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027424534

VL - 4

SP - 509

EP - 516

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 5

ER -